The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective ...

The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see ...

The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in ...

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a ...

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of ...

NEW YORK – A buzzy San Francisco-based biotech called Siren will test its adeno-associated virus (AAV) gene therapy and cytokine immunotherapy mashup for the first time in humans, the company said ...

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after ...

NEW YORK – Revolution Medicines on Thursday said it started treating patients with RAS G12V-mutated solid tumors in a Phase I trial of its RAS inhibitor RMC-5127. In the trial, Revolution will enroll ...

Moderna will get $50 million upfront and up to $110 million in near-term development and regulatory milestone payments, among other financial terms.